Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Calumet Specialty Products Partners, L.P. (CLMT)

The law firm of Kirby McInerney LLP is investigating potential claims against Calumet Specialty Products Partners, L.P. (“Calumet” or the “Company”) (NASDAQ:CLMT). The investigation concerns whether Calumet and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On February 23, 2024, Calumet released its fourth quarter and full year 2023 financial results and disclosed that its financial statements for the fiscal year ended December 31, 2022, and the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023 should no longer be relied upon due to “an error in the presentation of net income.” On this news, the price of Calumet shares declined by $0.61 per share, or approximately 3.5%, from $17.21 per share on February 22, 2024 to close at $16.60 on February 23, 2024.

If you purchased or otherwise acquired Calumet securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.